Roche's Genentech spends $15M to rocket into GenEdit’s NanoGalaxy
The next wave of gene editing advances will likely center not only on efficacy but on the diversity of where the therapies can be delivered, and Genentech is signing a new deal to keep up with the | Roche is the latest large pharma to buy into GenEdit's nanoparticle delivery tech for gene editing therapies, paying $15 million upfront. The biotech previously added Eli Lilly as an investor and inked a partnership with Sarepta.
